Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Asia Congress 2021

Pfizer Corporation Hong Kong Limited - Optimising treatment in ALK+ NSCLC: Debate and Ongoing Conversations

Expert debate: Management options in ALK+ NSCLC

Date

19 Nov 2021

Session

Pfizer Corporation Hong Kong Limited - Optimising treatment in ALK+ NSCLC: Debate and Ongoing Conversations

Presenters

Alona Zer

Authors

S.I. Ou1, A. Zer2

Author affiliations

  • 1 Medicine Department, UCI Health Chao Family Comprehensive Cancer Center, 92868 - Orange/US
  • 2 Medical Oncology, Rabin Medical Center Davidoff Cancer Centre, Beilinson Campus, 4941492 - Petah Tikva/IL

Resources

Login to get immediate access to this content.

If you do not have an ESMO account, please create one for free.

Login

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.